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Objectives: To assess the treatment effect of TAVR versus SAVR on clinical outcomes to 3 years
in patients stratified by chronic kidney disease (CKD) by retrospectively studying patients ran-
domized to TAVR or SAVR.
Background: The impact of CKD on mid-term outcomes of patients undergoing TAVR versus
SAVR is unclear.
Methods: Patients randomized to TAVR or SAVR in the CoreValve US Pivotal High Risk Trial
were retrospectively stratified by eGFR: none/mild or moderate/severe CKD. To evaluate the
impact of baseline CKD in TAVR patients only, all patients undergoing an attempted TAVR
implant in the US Pivotal Trial and CAS were stratified by baseline eGFR into none/mild, moder-
ate, and severe CKD. The primary endpoint was major adverse cardiovascular and renal events
(MACRE), a composite of all-cause mortality, myocardial infarction, stroke/TIA, and new require-
ment of dialysis.
Results: Moderate/severe CKD was present in 62.7% and 60.7% of high-risk patients random-
ized to TAVR or SAVR, respectively. Baseline characteristics were similar between TAVR and
SAVR patients in both CKD subgroups, except for higher rates of diabetes and higher serum cre-
atinine in SAVR patients. Among high-risk patients with moderate/severe CKD, TAVR provided
a lower 3-year MACRE rate compared with SAVR: 42.1% vs. 51.0, P = .04. Of 3,733 extreme-
and high-risk TAVR patients, 39.9% had none/mild, 53.8% moderate, and 6.4% severe CKD.
Worsening baseline CKD was associated with increased 3-year MACRE rates [none/mild 51.5%,
moderate 54.5%, severe 63.1%, P = .001].
Conclusions: TAVR results in lower 3-year MACRE versus SAVR in high-risk patients with mod-
erate/severe CKD. In patients undergoing TAVR, worsening CKD increases mid-term mortality
and MACRE. Randomized trials of TAVR vs. SAVR in patients with moderate-severe CKD would
help elucidate the best treatment for these complex patients.
Trial Registration: CoreValve US Pivotal Trial: NCT01240902.
CoreValve Continued Access Study: NCT01531374.
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1 | INTRODUCTION
The presence of advanced chronic kidney disease (CKD) significantly
worsens the short- and mid-term clinical outcomes of patients under-
going surgical aortic valve replacement (SAVR) for severe aortic steno-
sis (AS), with operative mortality as high as 21%1. Transcatheter aortic
valve replacement (TAVR) has emerged as a less invasive alternative
for patients with severe AS2,3.
The feasibility of TAVR or SAVR in patients with CKD has been
shown in observational studies4–10. Worsening CKD has been shown
to be associated with higher incidence of major bleeding and vascular
complications, as well as increased all-cause mortality rates11–13. The
impact of CKD on the mid-term outcomes of patients undergoing
TAVR versus SAVR is not known.
The primary aim of this study was to assess the treatment effect
of TAVR versus SAVR on the clinical outcomes to 3 years of patients
with varying degrees of CKD randomized in the CoreValve US Pivotal
High Risk Trial. The secondary aim was to assess the impact of CKD
on clinical outcomes to 3 years in all extreme-risk and high-risk
patients undergoing TAVR as part of the CoreValve US Pivotal Trial
and Continued Access Study (CAS).
2 | METHODS
2.1 | Study design
The CoreValve US Pivotal Trial was a prospective, controlled, multi-
center clinical trial conducted in patients with severe symptomatic AS
and extreme- or high-surgical risk at 45 sites in the United States.
Details of the study design and methodology have been previously
published14,15. At each site, the institutional review board approved
the study protocol, and all patients provided written informed con-
sent. The present analysis comprises extreme- and high-risk patients
from the CoreValve US Pivotal Extreme Risk Trial, Pivotal High Risk
Trial, and CAS as further described below.
2.2 | Patient selection
Trial inclusion/exclusion criteria have been previously published14,15.
Patients randomized in the US Pivotal High Risk Trial to TAVR or
SAVR who received an attempted implant were stratified into none/
mild or moderate/severe CKD according to their baseline renal func-
tion and their outcomes were evaluated. The Modification of Diet in
Renal Disease equation was used to calculate the estimated glomeru-
lar filtration (eGFR) from the patient's age, sex, race and baseline
serum creatinine. Patients without available baseline renal function data
were excluded from this analysis. Patients with end-stage renal disease
requiring chronic dialysis or those with an eGFR of ≤20 mL/min/1.73 m2
were excluded from the CoreValve US Pivotal Trial and CAS14,15. Due to
the small number of patients with severe CKD precluding meaningful anal-
ysis if evaluated separately, they were combined with those with moder-
ate CKD and only two groups, none/mild (eGFR>60 mL/min/1.73 m2) or
moderate/severe (eGFR≤60 mL/min/1.73 m2), were evaluated.
To evaluate the impact of baseline CKD in TAVR patients only, all
patients undergoing an attempted TAVR implant in the US Pivotal
Trial and CAS were stratified by baseline eGFR into none/mild
(eGFR>60 mL/min/1.73 m2), moderate (eGFR 30-60 mL/min/1.73
m2), and severe (eGFR<30 mL/min/1.73 m2) CKD and their clinical
outcomes assessed.
2.3 | Study endpoints
The primary endpoint is the composite of major adverse cardiovascu-
lar and renal events (MACRE) at 3 years, which included all-cause
mortality, any stroke/TIA, myocardial infarction, and new requirement
of dialysis. Individual components of MACRE and other clinical end-
points are also reported. Definitions of clinical endpoints are based on
the Valve Academic Research Consortium14–16.
2.4 | Statistical analysis
Categorical variables were compared using the Fisher exact test or
the chi-square test. Continuous variables are presented as mean 
standard deviation, with a t-test used for comparisons between two
groups and ANOVA used for comparisons across 3 groups. The Kaplan-
Meier estimates were used to construct survival and MACRE curves
based on all available follow-up data for the time-to-event analysis.
Differences in event rates were evaluated using the log-rank test. All
testing used a 2-sided α level of 0.05. For the predictors of mortality
analysis, variables were selected based on clinical relevance. Cox pro-
portional hazards survival models were used for 1-year mortality uni-
variable and multivariable modeling analysis. Variables for inclusion in
the Cox model for 1-year mortality were selected based on clinical rel-
evance (Supporting Information Table S1). Multivariable predictors
were identified from univariable predictors with P ≤ .05. A stepwise
procedure was performed to determine the final model. The signifi-
cance level thresholds for entry and exit of independent variables
were set at 0.10. Statistical analyses were performed with the use of
SAS software, version 9.2 or above (SAS Institute, Cary, NC).
3 | RESULTS
3.1 | High-risk patient characteristics
Patients randomized as part of the US Pivotal High Risk Trial were
stratified according to their CKD (none/mild vs. moderate/severe) to
compare the treatment effect of TAVR versus SAVR on clinical out-
comes (Figure 1). Among 871 patients enrolled, 797 underwent ran-
domization, with 391 patients among the attempted TAVR group and
359 patients in the attempted SAVR group. Moderate/severe CKD
was present in 60.7% of high-risk patients randomized to SAVR and in
62.7% of patients randomized to TAVR. Baseline characteristics were
similar between TAVR and SAVR patients in both CKD subgroups,
except for higher rates of diabetes and higher serum creatinine in
SAVR patients and a higher frequency of hostile mediastinum among
TAVR patients in the none/mild CKD group (Table 1).
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3.2 | Clinical outcomes after TAVR or SAVR
At 3-year follow up, the MACRE rate was lower in TAVR patients
compared with SAVR patients in the moderate/severe CKD group
(42.1% vs. 51.0%, P = .04) but not in the none/mild CKD group. There
were no differences in all-cause mortality, MI or all stroke/TIA or need
for new dialysis among groups. AKI was less frequent among TAVR as
compared with SAVR patients in both the none/mild (0.7% vs. 10.7%,
P < .001) and moderate/severe (9.6% vs. 18.2%, P = .001) CKD
groups. Life-threatening or disabling bleeding was lower among TAVR
compared with SAVR patients in both none/mild (15.8% vs. 33.7%,
P < .001) and moderate/severe (20.7% vs. 46.4%, P < .001) CKD
groups. Major vascular complications and need for new permanent
pacemaker were more frequent among TAVR compared with SAVR
patients in both CKD groups (Table 2, Figure 2).
3.3 | TAVR patient characteristics
To look at TAVR patients in isolation, 3,733 extreme- and high-risk
patients who underwent TAVR in the CoreValve US Pivotal Trial and
CAS (Supporting Information Figure S1) were stratified according to
their baseline eGFR: none/mild (n = 1,488, 39.9%), moderate
(n = 2,007, 53.8%), or severe (n = 238, 6.4%) CKD. Baseline clinical
and echocardiographic as well as procedural characteristics are pre-
sented in Table 3. Patients in the none/mild CKD group were younger,
and male sex and hostile mediastinum were more frequent. Patients in
the severe CKD group had a higher mean STS-PROM and logistic
EuroSCORE, and a higher incidence of comorbidities than patients
with none/mild or moderate CKD (Table 3).
3.4 | Clinical outcomes: TAVR patients
Worsening CKD was associated with a higher rate of MACRE at
3 years (Table 4). The difference in MACRE was driven predominantly
by an increase in new requirement for dialysis and the all-cause mor-
tality rate in patients with severe CKD. The 3-year MACRE (none/mild
51.5%, moderate 54.5%, severe CKD 63.1%, log-rank P = .001) and
all-cause mortality (none/mild 44.1%, moderate 46.1%, severe CKD
56.0%, log-rank P = .01) rates were significantly higher for the severe
CKD group (Figure 3). Three-year rates of new requirement of dialysis,
cardiovascular mortality, major bleeding, and acute kidney injury were
significantly higher in patients with severe CKD (Table 4).
3.5 | Predictors of 1-year all-cause mortality for
TAVR patients with moderate/severe CKD
A Cox regression model was built to identify covariates associated
with 1-year all-cause mortality in patients with moderate/severe
CKD. Albumin <3.3 g/dL, male sex, BMI <21 kg/m2, falls in the past
6 months, home oxygen, assisted living residents, baseline moderate/
FIGURE 1 Patient flow diagram for the high-risk analysis. The “attempted TAVR” and “attempted SAVR” cohorts include all patients randomized
to TAVR or SAVR who received an attempted implant (also includes intraprocedural deaths or other patients who may not have received an
implant). Abbreviations: CKD: chronic kidney disease; eGFR: estimated Glomerular Filtration Rate
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severe baseline mitral regurgitation, peripheral vascular disease, prior
stroke/ TIA, moderate/severe baseline tricuspid regurgitation, STS risk
score > 7%, and estimated volume of iodinated contrast media used
(per 10 cc) were found to be predictors of 1-year all-cause mortality.
Patients undergoing ilio-femoral access were less likely to die after
1 year (Figure 4).
TABLE 1 Baseline clinical characteristics in high-risk patients, TAVR vs. SAVR
None/mild CKD Moderate/severe CKD
N = 285 N = 460
TAVR SAVR TAVR SAVR
Demographics (N = 145) (N = 140) P-value (N = 244) (N = 216) P-value
Age (years) 82.5  7.9 82.7  6.9 0.75 83.5  6.6 83.7  5.9 0.81
Body surface area (m2) 1.8  0.2 1.9  0.3 0.50 1.9  0.2 1.9  0.2 0.88
Men 78 (53.8%) 83 (59.3%) 0.35 129 (52.9%) 102 (47.2%) 0.23
NYHA class III/IV 120 (82.8%) 123 (87.9%) 0.22 212 (86.9%) 188 (87.0%) 0.96
STS score (risk of mortality, %) 6.2  2.6 6.5  2.9 0.42 7.9  3.1 8.2  3.4 0.36
Diabetes mellitus 39 (26.9%) 64 (45.7%) 0.001 96 (39.3%) 97 (44.9%) 0.23
Serum creatinine (mg/dl) 0.8  0.2 0.9  0.2 0.04 1.4  0.4 1.4  0.4 0.96
Hypertension 136 (93.8%) 131 (93.6%) 0.94 234 (95.9%) 211 (97.7%) 0.28
Peripheral vascular disease 60 (41.4%) 61 (43.6%) 0.71 98 (40.7%) 87 (40.7%) >0.99
Prior stroke 18 (12.4%) 22 (15.7%) 0.42 31 (12.7%) 27 (12.6%) 0.96
Chronic lung disease/COPD 69 (47.6%) 66 (47.1%) 0.94 106 (43.4%) 95 (44.0%) 0.91
Coronary artery disease 103 (71.0%) 101 (72.1%) 0.84 190 (77.9%) 169 (78.2%) 0.92
Coronary artery bypass surgery 45 (31.0%) 40 (28.6%) 0.65 69 (28.3%) 71 (32.9%) 0.29
Percutaneous coronary intervention 47 (32.4%) 48 (34.3%) 0.74 85 (34.8%) 87 (40.3%) 0.23
Balloon valvuloplasty 6 (4.1%) 11 (7.9%) 0.19 17 (7.0%) 11 (5.1%) 0.40
Previous myocardial infarction 35 (24.1%) 36 (25.7%) 0.76 63 (25.8%) 54 (25.0%) 0.84
Congestive heart failure 141 (97.2%) 133 (95.0%) 0.37 231 (94.7%) 211 (97.7%) 0.10
Atrial fibrillation/atrial flutter 51 (35.2%) 58 (41.4%) 0.28 109 (44.9%) 106 (49.1%) 0.37
Chest wall deformity 6 (4.1%) 1 (0.7%) 0.12 3 (1.2%) 0 (0.0%) 0.25
Hostile mediastinum 8 (5.5%) 1 (0.7%) 0.04 7 (2.9%) 4 (1.9%) 0.55
Abbreviation: COPD, chronic obstructive pulmonary disease.
Continuous data are presented as mean  standard deviation. Categorical data are presented as no. (%) reflecting missing data.
TABLE 2 Three-year outcomes in high-risk patients, TAVR vs. SAVR
None/mild CKD Moderate/severe CKD
N = 285 N = 460
TAVR SAVR TAVR SAVR
P valueN = 145 N = 140 P value N = 244 N = 216
MACRE 53 (38.1%) 62 (45.8%) 0.12 101 (42.1%) 105 (51.0%) 0.04
New requirement of dialysis 2 (1.4%) 2 (1.4%) 0.97 15 (7.2%) 19 (9.2%) 0.23
Myocardial infarction 4 (3.6%) 3 (2.7%) 0.80 5 (2.2%) 5 (2.8%) 0.78
All stroke or TIA 17 (12.7%) 25 (21.1%) 0.10 35 (15.8%) 38 (20.8%) 0.23
All-cause mortality 42 (30.2%) 48 (36.0%) 0.25 82 (34.3%) 84 (41.7%) 0.10
Cardiovascular 29 (21.8%) 35 (27.6%) 0.25 53 (23.3%) 50 (27.4%) 0.41
Reintervention 4 (3.0%) 1 (0.9%) 0.21 5 (2.2%) 0 (0.0%) 0.04
All stroke 14 (10.5%) 23 (19.2%) 0.07 30 (13.6%) 35 (19.2%) 0.15
Major stroke 9 (6.6%) 15 (12.9%) 0.14 19 (8.7%) 20 (11.2%) 0.46
Bleeding (life-threatening or disabling/major) 56 (39.7%) 90 (64.5%) <0.001 125 (51.9%) 169 (79.4%) <0.001
Life-threatening or disabling 22 (15.8%) 46 (33.7%) <0.001 49 (20.7%) 97 (46.4%) <0.001
Major bleed 38 (26.8%) 54 (39.9%) 0.03 87 (36.7%) 85 (40.7%) 0.36
Major vascular complication 11 (7.8%) 3 (2.1%) 0.04 16 (6.7%) 4 (1.9%) 0.01
Acute kidney injury 1 (0.7%) 15 (10.7%) <0.001 23 (9.6%) 39 (18.2%) 0.01
Aortic valve hospitalization 29 (22.1%) 25 (20.4%) 0.80 65 (30.8%) 39 (23.3%) 0.08
New permanent pacemaker 34 (24.7%) 15 (11.8%) 0.01 68 (30.3%) 31 (16.5%) <0.001
Abbreviations: CKD, chronic kidney disease; MACRE, major adverse cardiovascular and renal events; TIA, transient ischemic attack.
Values are Kaplan-Meier estimates and are reported as no. of patients with the event (%). P-value is calculated based on Log-rank test.
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4 | DISCUSSION
The principal findings of this analysis are: (1) moderate to severe
CKD was frequent, being present in over 60% of high or extreme-risk
TAVR and high-risk SAVR patients in the present study; (2) in high-risk
patients with moderate/severe CKD, TAVR provided better clinical
outcomes when compared with SAVR, with a significantly lower
3-year rate of MACRE; (3) in high- risk patients who underwent TAVR,
severe CKD was associated with an increased incidence of the
mid-term adverse clinical outcomes, including all-cause mortality and
MACRE; (4) several baseline clinical and some procedural features
were found to be associated with the 1-year all-cause mortality
among high- or extreme-risk patients with moderate/severe CKD
undergoing TAVR.
Consistent with others, we found a high frequency of moder-
ate/severe CKD among the high- to extreme-risk patients under-
going TAVR and high-risk patients randomized to SAVR11,17,
which is likely to be multifactorial11,12,18–20. While previous
TABLE 3 Baseline demographics and procedural characteristics, all TAVR patients
Demographics and procedural characteristics
None/mild CKD Moderate CKD Severe CKD
P-valueN = 1,488 N = 2,007 N = 238
Age (years) 82.1  8.5 84.0  7.1 83.3  7.2 <0.001
Body surface area (m2) 1.8  0.2 1.9  0.3 1.9  0.2 0.09
Men 862 (57.9%) 1,031 (51.4%) 125 (52.5%) <0.001
NYHA class III/IV 1,251 (84.1%) 1,776 (88.5%) 217 (91.2%) <0.001
STS PROM score (%) 7.3  4.0 9.6  4.7 12.8  5.6 <0.001
Logistic EuroSCORE (%) 20.1  15.1 23.0  15.8 27.5  18.5 <0.001
Diabetes mellitus 478 (32.1%) 800 (39.9%) 113 (47.5%) <0.001
Serum creatinine (mg/dL) 0.9  0.2 1.3  0.3 2.1  0.4 <0.001
Hypertension 1,343 (90.3%) 1,890 (94.2%) 231 (97.1%) <0.001
Peripheral vascular disease 646 (43.5%) 927 (46.3%) 122 (51.5%) 0.04
Prior stroke 171 (11.5%) 282 (14.1%) 36 (15.1%) 0.06
Chronic lung disease/COPD 825 (55.4%) 1,068 (53.2%) 133 (56.1%) 0.36
Coronary artery disease 1,139 (76.5%) 1,609 (80.2%) 204 (85.7%) 0.001
Coronary artery bypass surgery 494 (33.2%) 723 (36.0%) 97 (40.8%) 0.04
Percutaneous coronary intervention 553 (37.2%) 778 (38.8%) 106 (44.5%) 0.09
Balloon valvuloplasty 161 (10.8%) 277 (13.8%) 36 (15.1%) 0.02
Congestive heart failure 1,448 (97.3%) 1,962 (97.8%) 232 (97.5%) 0.70
Atrial fibrillation/atrial flutter 597 (40.2%) 933 (46.7%) 113 (47.5%) <0.001
Hostile mediastinum 151 (10.2%) 144 (7.2%) 8 (3.4%) 0.001
Baseline echocardiographic data
Mean aortic valve gradient (mm hg) 48.5  14.0 47.2  12.7 45.9  12.1 0.002
Mean cardiac index (L/min/m2) 2.68  0.92 2.62  0.99 2.58  0.90 0.09
Stroke volume (mL) 69.4  23.4 70.1  27.0 71.4  25.2 0.49
Stroke volume index 38.1  12.9 38.1  14.3 38.3  13.3 0.97
Left ventricular ejection fraction (%) 54.5  13.5 53.5  13.9 52.7  13.8 0.047
Procedural characteristics
Total procedure time (min) 56.2  36.9 55.9  37.4 52.6  29.3 0.38
Type of anesthesia 0.16
General 1,352 (91.2%) 1,855 (92.9%) 224 (94.5%)
Conscious sedation 128 (8.6%) 135 (6.8%) 13 (5.5%)
Access site
Ilio-femoral 1,211 (81.7%) 1,602 (80.3%) 190 (80.2%) 0.53
Subclavian/axillary 89 (6.0%) 110 (5.5%) 13 (5.5%)
Direct aortic 181 (12.2%) 284 (14.2%) 34 (14.3%)
Other 2 (0.1%) 0 (0.0%) 0 (0.0%)
Successful implantationa 1,456 (98.2%) 1,965 (98.5%) 233 (98.3%) 0.77
Conversion to open heart surgery 4 (0.3%) 1 (0.1%) 0 (0.0%) 0.18
Volume of contrast used (cc) 164.6  91.9 156.7  94.4 133.4  86.3 <0.001
Length of hospital stay (days) 7.9  6.6 8.6  7.5 9.0  7.2 0.01
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
Continuous data are presented as mean  standard deviation. Categorical data are presented as no. (%), reflecting missing data.
aSuccessful vascular access, delivery and deployment of the device.
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studies11,12,18 provided short-term outcomes, the UK TAVI regis-
try18 and the present study provide mid-term (3-year) outcomes.
Additionally, unlike previous studies12,18,20, our analysis
specifically evaluated the impact of CKD on the outcomes of
high- and extreme-risk patients undergoing TAVR similar to one
prior study from the PARTNER 1 trial11.
FIGURE 2 MACRE and all-cause mortality rates, TAVR vs. SAVR in high-risk patients. MACRE composite outcome in high-risk TAVR (red lines)
vs. SAVR (blue lines) patients with none/mild CKD (A) and moderate/severe CKD (B), and all-cause mortality in TAVR (red lines) vs. SAVR (blue
lines) for patients with none/mild CKD (C) and moderate/severe CKD (D). Values are KM % (95% CI)
TABLE 4 Three-year outcomes, all TAVR patients
None/mild CKD Moderate CKD Severe CKD
P valueN = 1,488 N = 2,007 N = 238
MACRE 624 (51.5%) 914 (54.5%) 125 (63.1%) 0.001
New requirement of dialysis 24 (2.1%) 90 (5.9%) 27 (15.8%) <0.001
Myocardial infarction 48 (4.7%) 50 (3.7%) 10 (5.1%) 0.17
All stroke or TIA 173 (14.8%) 261 (17.8%) 29 (17.1%) 0.44
All-cause mortality 514 (44.1%) 747 (46.1%) 103 (56.0%) 0.01
Cardiovascular 327 (29.0%) 520 (33.7%) 70 (42.3%) 0.01
Reintervention 20 (1.5%) 22 (1.3%) 3 (1.3%) 0.81
All stroke 140 (11.8%) 215 (14.7%) 25 (15.0%) 0.39
Major stroke 82 (7.4%) 128 (8.9%) 15 (8.8%) 0.51
Bleeding (life-threatening or disabling/major) 590 (42.4%) 901 (47.5%) 122 (57.0%) <0.001
Life-threatening or disabling 246 (18.5%) 357 (20.3%) 46 (22.2%) 0.41
Major bleed 394 (28.6%) 620 (32.7%) 86 (41.0%) <0.001
Major vascular complication 111 (7.5%) 150 (7.5%) 20 (8.9%) 0.86
Acute kidney injury 72 (4.9%) 267 (13.5%) 66 (28.3%) < 0.001
Aortic valve hospitalization 268 (24.8%) 491 (33.4%) 71 (44.9%) < 0.001
New permanent pacemaker 362 (27.6%) 555 (31.2%) 64 (34.2%) 0.08
Abbreviations: CKD, chronic kidney disease; MACRE, major adverse cardiovascular and renal events; TIA, transient ischemic attack.
Values are Kaplan-Meier estimates and are reported as no. of patients with the event (%). P-value is calculated based on Log-rank test.
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The composite endpoint of MACRE is one of the unique features
of the present analysis. The MACRE rate was significantly increased
with worsening CKD up to 3 years after TAVR and driven by an
increase in all-cause mortality and new requirement for dialysis. We
also found increased new requirement for dialysis according to CKD.
The risk of AKI increased as CKD worsened and likely contributed to
the new requirement of dialysis rate. These results are consistent with
previous studies which reported only short-term data11.
As TAVR has emerged as an effective therapy for symptomatic
severe AS, the question of offering TAVR rather than SAVR to
patients with CKD has become increasingly important. We found a
significantly lower 3-year rate of MACRE with TAVR compared with
SAVR in patients with moderate/severe CKD (P = .04). The rates of
bleeding (major/life-threatening or disabling) and AKI were consis-
tently higher for SAVR patients. The higher rates of bleeding among
SAVR patients may have also resulted in a higher AKI rate. Previous
results from the CoreValve High Risk Pivotal Trial demonstrated
increased mortality in SAVR patients with AKI, but not TAVR patients
with AKI13. The increase in bleeding rates in SAVR cases may be
related to the platelet dysfunction associated with renal disease, with
a further negative impact on platelet function due to cardiopulmonary
bypass. These findings suggest worse outcomes with SAVR rather
than TAVR in high-risk patients with moderate to severe CKD and are
consistent with a retrospective analysis not confined to high- or
extreme-risk patients by Nguyen et al.10.
In patients with moderate/severe CKD, we found baseline clinical
features associated with increased disease burden and frailty to be
predictors of 1-year all-cause mortality, consistent with previous stud-
ies11,21,17. Also consistent with others22,23, we found multi-valvular
involvement including tricuspid regurgitation to be associated with
1-year all-cause mortality, thus, the presence of such multi-valvular
pathology should be carefully considered in counseling patients.
We found procedural characteristics to be associated with 1-year
all-cause mortality, following TAVR. Consistent with others, we found
the volume of iodinated contrast used, especially in patients with
baseline renal dysfunction, to be associated with increased risk of
FIGURE 4 Multivariable predictors of 1-year mortality in all TAVR patients with moderate/severe CKD all TAVR patients with eGFR ≤60 mL/
min/1.73 m2 were included. Variables were selected from univariable predictors with P-value ≤0.05. Stepwise method with thresholds for entry
and exit = 0.10
FIGURE 3 MACRE composite endpoint (A) and all-cause mortality (B) for all TAVR patients up to 3 years post-procedure. Patients were stratified
by none/mild (red lines), moderate (blue lines), or severe (black lines) baseline CKD. Values are KM % (95% CI)
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acute kidney injury and elevated 1-year mortality highlighting the
importance of minimizing contrast use24–26. Consistent with the liter-
ature, we found a higher rate of vascular complications and the need
for permanent pacemaker placement with TAVR. However, both of
these complications will likely continue to decline and may not pose a
disadvantage with TAVR rather than a SAVR approach27,28. Also con-
sistent with previous literature11, we found ilio-femoral access to be
protective, likely due to the less invasive nature of this approach, and
the fact that those undergoing alternative access TAVR often have a
higher burden of disease.
There are several limitations to consider. First, the present study
was a post-hoc analysis of patients included in the CoreValve US Piv-
otal Extreme Risk and High Risk Trial and CAS. The number of
patients in the severe CKD group was small. The new requirement of
dialysis was not a prespecified data collection endpoint, and as such
was manually collected and reviewed, and not adjudicated by the Clin-
ical Events Committee. Due to a small sample size in the high-risk
cohort with severe CKD, we were only able to perform a 2-group
(none/mild and moderate/severe) comparison between TAVR and
SAVR, which limits the applicability of our results in patients with
severe CKD. Patients with end stage renal disease requiring chronic
dialysis or those with an eGFR of ≤20 mL/min/1.73 m2 were
excluded from the CoreValve US Pivotal Trial and the CAS; therefore,
we were unable to provide outcomes with TAVR or SAVR for this
sub-group in the present analysis.
5 | CONCLUSION
In conclusion, TAVR was found to provide a lower 3-year rate of
MACRE when compared with SAVR in high-risk patients with moder-
ate/severe CKD suggesting TAVR is the preferred strategy for the
treatment of these complex patients. Additionally, in patients under-
going TAVR, worsening CKD increases short- and mid-term all-cause
mortality and the incidence of MACRE. Clinical features of increased
disease burden, frailty, and procedural characteristics were found to
be predictors of 1-year all-cause mortality in patients with moderate/
severe CKD, emphasizing the need for a careful risk stratification and
choice of procedural approach in such patients.
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